Thrombosis Drugs Market Size by Drug Class, Disease Type, Distribution Channel, Region – Revenue Pool Analysis, Margin Structure Assessment, Capital Flow Trends, Competitive Benchmarking & Forecast to 2034
Overview
Thrombosis Drugs Market is expected to reach US$ 41.09 Bn. at a CAGR of 9.35% during the forecast period 2034.
Thrombosis Drugs Market Drivers and Restrains:
Thrombosis drugs are used to prevent or treat the blood clot, which can cause different thrombotic events. The drugs for the treatment of thrombosis contain anticoagulants drugs and thrombin inhibitors drug. These drugs reduce the clotting power of blood and consequently the probabilities of thrombosis events such as pulmonary embolism, atrial fibrillation, and deep vein thrombosis. These drugs are accessible in the form of injection, capsule, and tablet.
Thrombosis Drugs Market Size, Growth & Share Analysis
To know about the Research Methodology :- Request Free Sample Report
The growing consumption of alcohol and tobacco with obesity, which adds on a high risk of developing symptoms like high blood pressure on veins for a long period, which leads to several thrombosis related complications. The market for thrombosis drugs is driven by an increasing the burden of cardiovascular disease & trauma cases, rising geriatric population and the increasing R&D expenditure in the field of hematological disorders. Additionally, increasing focus on the development of low-cost drugs and large patient pool contributes to the growth of thrombosis drugs market. Ongoing developments in thrombosis drugs, such as Revo Biologic’s ATryn with continuous infusion of drugs are likely drive the thrombosis drugs market during the forecast period.
The growing occurrences of deep vein thrombosis and research activities to develop innovative drugs provide an opportunity for enhanced and effective treatment, which are expected to support the market growth in the near future. However, side effects allied with thrombosis drugs and lack of awareness about the severity of thrombosis may restraining the market growth at global level. The high price of non-vitamin K oral anticoagulant drugs and the availability of generic drugs are likely to hinder the market growth during the forecast period.
Thrombosis Drugs Market Segment Analysis:
By drug class, the global thrombosis drugs market has been segmented into factor Xa inhibitor, heparin, and P2Y12 platelet inhibitor. The factor Xa inhibitor is expected to grow at the largest CAGR of xx% during the forecast period, owing to the high preference of anti-coagulant drugs. These drugs are mainly used for the prevention and treatment of pulmonary embolism and deep vein thrombosis.
Based on disease type, the global market has been segmented into pulmonary embolism, atrial fibrillation, and deep vein thrombosis. In terms of revenue, the pulmonary embolism segment led the market in 2025. The segment is projected to continue to dominate the market during the forecast period.
Thrombosis Drugs Market Regional Insights:
Geographically, the global thrombosis drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest market share in 2025, owing to the high prevalence of cardiovascular diseases, the upsurge in the demand for progressive treatment options, early adoption of new technologies, and presence of main key players in this region. Europe and the Asia-Pacific are largest market of market, owing to the presence of a diversified patient pool, emerging economies, and rise in collaboration of domestic and international companies with campaigns for awareness campaign in these regions, thus driving this market.
A report covers the recent development in market for market i.e. Grifols Therapeutics Inc. is a U.S.-based biotechnology company is expected to launch AT- lll, a new type of human recombinant thrombosis drugs for the indication of cardiac surgery cardiopulmonary bypass. In late 2025, Janssen Pharmaceuticals declared the launch of XARELTO (rivaroxaban) for reducing the sustained risk of recurrent venous thromboembolism (VTE). In September 2014, Mylan Inc., acquired the U.S. Commercialization, advertising, and Intellectual property rights relating to Arixtra (Fonaparinux Sodium) Injection and the Authorized generic of Arixtra from Aspen Global Incorporated. This acquisition enhanced Mylan Inc's expansion opportunities in the U.S. market.
Thrombosis Drugs Market Competitive landscape
Major Key players operating in this market are Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Johnson & Johnson, Sanofi, Pfizer, Inc. Manufacturers in the thrombosis drugs are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.
The objective of the report is to present comprehensive analysis of global market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region.
PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding global market dynamics, structure by analyzing the market segments, and project the global market size. Clear representation of competitive analysis of key players by drug class, price, financial position, product portfolio, growth strategies, and regional presence in the global market make the report investor’s guide.
Thrombosis Drugs Market Recent Development:
| Date | Company | Development | Impact |
| 11 February 2025 | Novartis | Novartis entered into a definitive agreement to acquire Anthos Therapeutics for $925 million upfront to secure full rights to abelacimab. | The acquisition expands Novartis' cardiovascular portfolio by adding a first-in-class Factor XI inhibitor aimed at stroke prevention and pulmonary embolism treatment. |
| 07 March 2025 | Lupin Limited | Lupin launched generic Rivaroxaban Tablets USP, 2.5 mg in the United States following final approval of its ANDA from the U.S. FDA. | The launch increases commercial access to low-dose Factor Xa inhibitor therapy for reducing major thrombotic vascular events in patients with peripheral artery disease. |
| 17 March 2025 | Genentech | Genentech received U.S. FDA approval for TNKase (tenecteplase) as a single five-second IV bolus for acute ischemic stroke. | The streamlined single-bolus thrombolytic therapy offers faster administration compared to standard infusions, significantly improving emergency intervention protocols for thromboembolic stroke. |
| 12 September 2025 | Cadrenal Therapeutics | Cadrenal Therapeutics completed the asset acquisition of eXIthera Pharmaceuticals, securing rights to Phase 2-ready intravenous Factor XIa inhibitor frunexian. | The deal strengthens Cadrenal’s acute anticoagulation pipeline targeting device-induced clot formation, catheter thrombosis, and hospital-based thromboprophylaxis. |
| 01 October 2025 | Lupin Limited | Lupin launched Rivaroxaban for Oral Suspension, 1 mg/mL in the United States as a generic equivalent to Xarelto®. | The introduction offers a liquid oral anticoagulant alternative tailored for pediatric populations requiring thromboprophylaxis after congenital heart procedures. |
| 05 May 2026 | Bayer | Bayer received U.S. FDA Priority Review designation for its novel oral Factor XIa inhibitor asundexian for secondary stroke prevention. | The expedited regulatory review timeline advances a next-generation anticoagulant offering efficacy in preventing recurrent ischemic events with lower major bleeding risk. |
Thrombosis Drugs Market Scope : Inquire before buying
| Thrombosis Drugs Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | US $ 41.09 Bn. |
| Forecast Period 2026 to 2034 CAGR: | 9.35% | Market Size in 2034: | US $ 91.87 Bn. |
| Segments Covered: | by Drug Class | Factor Xa Inhibitor Heparin P2Y12 Platelet Inhibitor |
|
| by Disease Type | Pulmonary Embolism Atrial Fibrillation Deep Vein Thrombosis |
||
| by Distribution Channel | Hospital Pharmacies Retail Pharmacies Online Pharmacies |
||
Thrombosis Drugs Market, by Region:
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America
Thrombosis Drugs Market, Key Players:
1. Bayer AG
2. Boehringer Ingelheim GmbH
3. Bristol-Myers Squibb
4. Johnson & Johnson
5. Sanofi
6. Pfizer, Inc.
7. Aspen Pharmacare Holdings
8. AstraZeneca plc,
9. Daiichi Sankyo
10. Baxter International Inc.
11. GlaxoSmithKline plc
12. Janssen Pharmaceuticals
13. Grifols Therapeutics Inc.
14. Mylan Inc.
15. Aurobindo Pharma
16. Biogen
17. DAIICHI SANKYO COMPANY, LIMITED
18. AuroMedics Pharma LLC
19. Vasudha Pharma
20. GoodRx, Inc
21. ITALFARMACO S.p.A
22. Inari Medical, Inc.
Frequently Asked Questions:
1. Which region has the largest share in Global Thrombosis Drugs Market?
Ans: North America region held the highest share in 2025.
2. What is the growth rate of Global Thrombosis Drugs Market?
Ans: The Global Thrombosis Drugs Market is expected to grow at a CAGR of 9.35% during forecast period 2026-2034.
3. What is scope of the Global Thrombosis Drugs market report?
Ans: Global Thrombosis Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Thrombosis Drugs market?
Ans: The important key players in the Global Thrombosis Drugs Market are – Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Johnson & Johnson, Sanofi, Pfizer, Inc., Aspen Pharmacare Holdings, AstraZeneca plc,, Daiichi Sankyo, Baxter International Inc.,
5. What is the study period of this market?
Ans: The Global Thrombosis Drugs Market is studied from 2020 to 2034.